Stuart Murray
Biohaven Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Epigenetics and DNA Methylation, Cancer, Hypoxia, and Metabolism, RNA modifications and cancer, Amino Acid Enzymes and Metabolism, Biochemical and Molecular Research
Most-Cited Works
- → Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation(2013)791 cited
- → mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer(2017)214 cited
- → IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition(2014)167 cited
- → PU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid Differentiation(2003)100 cited
- → Phosphorylation of the RNA Polymerase II Carboxy-Terminal Domain by the Bur1 Cyclin-Dependent Kinase(2001)100 cited
- → D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice(2014)86 cited
- → A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition(2019)72 cited
- → Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis(2008)48 cited
- → Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism(2014)43 cited
- → A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments(2011)19 cited